Caladrius Biosciences Inc (NASDAQ:CLBS) posted its quarterly earnings data on Thursday, May 18th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.40, reports. The company had revenue of $7.92 million during the quarter, compared to the consensus estimate of $9.50 million. Caladrius Biosciences had a negative return on equity of 1,834.48% and a negative net margin of 123.61%.
Caladrius Biosciences (NASDAQ:CLBS) opened at 4.55 on Tuesday. Caladrius Biosciences has a 12 month low of $2.65 and a 12 month high of $7.79. The firm’s 50-day moving average is $4.83 and its 200-day moving average is $4.43.
A number of research analysts have commented on the stock. Zacks Investment Research upgraded shares of Caladrius Biosciences from a “sell” rating to a “hold” rating in a research report on Monday, May 22nd. HC Wainwright set a $7.00 price target on shares of Caladrius Biosciences and gave the company a “buy” rating in a research report on Friday, May 19th.
Receive News & Ratings for Caladrius Biosciences Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Caladrius Biosciences Inc and related companies with our FREE daily email newsletter.